1+ mon, 1+ week ago   (542+ words) Replimune's immunotherapy for advanced melanoma, RP1, has been backed by an FDA advisory committee, even though there was considerable debate about the design of a clinical trial used to support its marketing application. The Cellular, Tissue and Gene Therapies Advisory Committee…...

1+ mon, 2+ week ago   (404+ words) AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side. Sales grew 6% to $30.7 billion in the first half, with operating profit shooting up 11% to…...

1+ mon, 3+ week ago   (503+ words) Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease, after preliminary results proved disappointing. Shares in the company were down almost 18% on the announcement, which said…...

1+ mon, 3+ week ago   (395+ words) The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the latest to make their intentions known. Attovia's IPO aims to raise funding for a pipeline of immunology and inflammation (I…...

2+ mon, 3+ day ago   (580+ words) Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) therapy, Wainua, missed the mark in a trial in patients with cardiomyopathy (CM). Ionis-partnered Wainua (eplontersen) was unable to show an improvement in…...

2+ mon, 1+ week ago   (602+ words) In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK polyomavirus, which can cause serious complications in some transplant patients. The French pharma group will pay €200 million ($228 million) to shareholders…...

3+ mon, 20+ hour ago   (493+ words) Novo Nordisk has become the latest pharma group to be targeted by a cyberattack, with the company revealing that some patient data has been "copied externally without authorisation." Preliminary investigations by the company have found that the breach involved "a…...

3+ mon, 1+ day ago   (543+ words) Takeda has issued a challenge to Bristol Myers Squibb after reporting top-line results from a head-to-head psoriasis study, which showed its TYK2 inhibitor zasocitinib was more effective than BMS's first-to-market Sotyktu. Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor…...

3+ mon, 4+ day ago   (598+ words) Johnson & Johnson has continued to build its presence in KRAS-targeting drugs for cancer with a $1 billion agreement to buy Firefly Bio and its degrader-antibody conjugate (DAC) platform. The all-cash deal comes just over two years after South San Francisco-based Firefly…...

3+ mon, 4+ day ago   (920+ words) Boehringer Ingelheim revealed more data behind previously reported top-line results for its dual-acting obesity drug survodutide, including strong activity against visceral and liver fat. The efficacy results were, however, undermined by safety concerns, dragging down the share price of Zealand…...